Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 6/20 | 0.57 |
| ▸ | METAP1 | P53582 | 2/20 | 0.42 |
| ▸ | ANPEP | P15144 | 6/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.39 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL5462387 | 0.94 | LAP3 (0.52) | LAP3METAP1ANPEPERAP1FDPS | |
| Phosphoric Acid SCHEMBL28448377 | 0.84 | LAP3 (0.60) | LAP3METAP1ANPEPERAP1ERAP2 | |
| Phosphoric Acid SCHEMBL29275124 | 0.84 | LAP3 (0.60) | LAP3METAP1ANPEPERAP1ERAP2 | |
| Pyrophosphoric Acid SCHEMBL8169753 | 0.84 | FDPS (0.50) | LAP3METAP1ANPEPERAP1ERAP2 | |
| SCHEMBL15226 | 0.83 | — | — | |
| SCHEMBL1217603 | 0.83 | — | — | |
| SCHEMBL1127507 | 0.83 | — | — | |
| Phosphoric Acid SCHEMBL28859152 | 0.81 | LAP3 (0.57) | LAP3METAP1ANPEPERAP1ERAP2 | |
| Phosphoric Acid SCHEMBL28859154 | 0.81 | LAP3 (0.57) | LAP3METAP1ANPEPERAP1ERAP2 | |
| Phosphoric Acid SCHEMBL27580550 | 0.81 | LAP3 (0.57) | LAP3METAP1ANPEPERAP1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021148-A1 | METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-01-22 | — | — | US | disclosed |
| US-12318413-B2 | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-06-03 | — | — | US | disclosed |
| US-12310996-B2 | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240173361-A1 | METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-30 | — | — | US | disclosed |
| US-20230109343-A1 | METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-06 | — | — | US | disclosed |
| US-11395838-B2 | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-07-26 | — | — | US | disclosed |
| US-20200129569-A1 | METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-04-30 | — | — | US | disclosed |
| CN-110483314-A | A kind of full green synthesis method and its device of chiral beta-alkamine compound | NEW MATERIAL AND INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE OF WENZHOU UNIV | 2019-11-22 | — | — | CN | disclosed |
| US-8980612-B2 | Fermentive production of four carbon alcohols | BUTAMAX ADVANCED BIOFUELS LLC (US) | 2015-03-17 | — | — | US | disclosed |
| US-8962298-B2 | Recombinant host cell comprising a diol dehydratase | BUTAMAX ADVANCED BIOFUELS LLC (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2010643-A2 | FERMENTIVE PRODUCTION OF FOUR CARBON ALCOHOLS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-2010664-A2 | FERMENTIVE PRODUCTION OF FOUR CARBON ALCOHOLS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008137403-A1 | METHOD FOR THE PRODUCTION OF 2-BUTANOL | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137404-A1 | METHOD FOR THE PRODUCTION OF 2-BUTANONE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20080274525-A1 | METHOD FOR THE PRODUCTION OF 2-BUTANOL | GEVO, INC. | 2008-11-06 | — | — | US | disclosed |
| US-20080274522-A1 | METHOD FOR THE PRODUCTION OF 2-BUTANONE | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-11-06 | — | — | US | disclosed |
| US-20070292927-A1 | producing 2-butanol and 2-butanone by the fermentive growth of a recombinant bacteria expressing a 2-butanol biosynthetic pathway | GEVO, INC. | 2007-12-20 | — | — | US | disclosed |
| WO-2007130521-A2 | FERMENTIVE PRODUCTION OF FOUR CARBON ALCOHOLS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007130518-A2 | FERMENTIVE PRODUCTION OF FOUR CARBON ALCOHOLS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259410-A1 | FERMENTIVE PRODUCTION OF FOUR CARBON ALCOHOLS | GEVO, INC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021148-A1 | METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME | PDCD1, CD274, PDCD1LG2 | LAP3 2518/4885METAP1 1898/4885ANPEP 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.